Synchronoss Technologies Inc (SNCR) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket
 


Synchronoss Technologies Inc  (NASDAQ: SNCR)

Synchronoss Technologies Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Synchronoss Technologies Inc in the third quarter 2025?
Synchronoss Technologies Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -22.87%.

Within the Cloud Computing & Data Analytics industry 64 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2984, from total ROE ranking in the second quarter 2025 at 3398.

What is ROE?




Return On Equity (Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
Y / Y Equity Change 56.8 % 61.45 % 47.92 % 11.8 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -10 -21 -2 6 -34
Return On Equity (TTM) -22.87 % -56.68 % -6.52 % 20.57 % -117.33 %
SNCR's Total Ranking # 2984 # 3398 # 2642 # 717 # 3755
Equity (TTM) in Millions 55 49 35 30 35
Seq. Equity Change 11.98 % 39.49 % 19.02 % -15.66 % 15.3 %
Seq. Net Income Change - - - - -

Return On Equity Company Ranking
Within: No.
Industry # 65
Sector # 397
Overall # 2984

Return On Equity Statistics
High Average Low
20.57 %
-32.55 %
-150.21 %
(Dec 31 2024)   (Sep 30 2019)



  News about Synchronoss Technologies Inc Return on Equity ROE

Clinuvel Unveils Revolutionary Vitiligo Program at AAD 2025 A New Era in Photomedicine

Clinuvel Unveils Revolutionary Vitiligo Program at AAD 2025: A New Era in Photomedicine MELBOURNE, Australia The future of dermatology is shining bright as Clinuvel Pharmaceuticals prepares to make a significant impact at the American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7 to 11, 2025. This landmark event, recognized as the world’s largest gathering of dermatology professionals, provides a pivotal platform for Clinuvel to debut its innovative Vitiligo program.Clinuvel, a world leader in photomedicine, plans an immersive exhibition designed to showcase the evolution of their groundbreaking work within the field. The exhibition invites attendees to not only explore the journey of photomedicine but also to engage with the latest advancements in treatments for skin conditions such as vitiligo a disorder affecting more than 2% of the global population characterized by the loss of skin pigment.




SNCR Annual Return On Equity (Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
Total Equity in Millions 30 27 68 91 43
Y / Y Equity Change 11.8 % -60.89 % -25.02 % 109.84 % -43.11 %
Net Income in Millions 6 -55 -8 -23 -10
Y / Y Net Income Change - - - - -
Return On Equity 20.67 % -204.91 % -11.33 % -25.43 % -23.93 %





Annual Roe Comment
In 2024 ROE improved to 20.67 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Cloud Computing & Data Analytics Industry Roe Trends and Statistics
Technology Sector Return On Equity Statistics
SNCR's' Return on Equity at Yahoo Finance
SNCR's Roe Ratio versus Cloud Computing & Data Analytics Industry, Technology Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SNCR's Competitors
Subscribers only: Roe for Synchronoss Technologies Inc's Suppliers
Subscribers only: Return On Equity for SNCR's Customers




Companies with similar Return On Equity at Sep 30 2025, within Technology Sector ROE


Date modified: 2026-09-12T06:15:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.